Compare Charles River Laboratories Intl. Inc (CRL) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Raymond James Financial, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while Raymond James Financial, Inc. trades at $157.94 (market cap $30.51B). The key difference: Raymond James Financial, Inc. is far larger — about 2.1× Charles River Laboratories Intl. Inc's market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Raymond James Financial, Inc. for 75 Days on average.
| CRL | RJF | |
|---|---|---|
Market Cap | $14.23B | $30.51B |
Volume | 1,176,885 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $310.77 | $181.18 |
52-Week Low | $149.93 | $140.89 |
Typical Hold Time | 33 Days | 75 Days |
Enterprise Value | $17.06B | $24.37B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Raymond James Financial (RJF) trades at $159.04, up 1.11% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.14 surpassing the $2.93 estimate. Revenue has grown steadily from $10.9B in 2022 to $13.84B in 2025, while net income reached $2.14B. A quarterly dividend of $0.54 was declared, payable in October 2026.
The outlook is supported by solid fundamentals, including a P/E of 13.83 and ROE of 18.48%, but risks include volatile cash flows from investing activities and rising expenses. Analysts are neutral with a consensus price target of $184.00, implying potential upside. Investor sentiment is mixed amid recent institutional buying and selling activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
